Ravi Vij, MD, MBA, attended Maulana Azad Medical College, University of Delhi, New Delhi, India, before completing an internal medicine residency at Rush Presbyterian St. Luke’s Medical Center, Chicago, IL, and fellowships in medical oncology/hematology and bone marrow transplantation at Washington University, St. Louis, MO. He also completed a Healthcare MBA at George Washington University in 2012.
Prof. Vij remained at the Washington University School of Medicine, specializing in bone marrow transplantation and leukemia, where he became a Professor of Medicine in 2015. In 2016, he took on the additional role of Medical Director at the Siteman Cancer Center. Prof. Vij currently serves on the myeloma, core transplant and leukemia Cancer and Leukemia Group B (CALGB) committees, as well as the MMRC steering committee and has previously been a member of the Education Committee of the American Society of Clinical Oncology and the American Society of Hematology Scientific Committee on Plasma Cell Dyscrasias.
Speaking on bone marrow transplantation, myeloma, and AML/MDS
Prof. Vij’s expertise covers stem cell transplantation for hematologic malignancies, multiple myeloma, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS). He has been the principal investigator in numerous pivotal national clinical trials looking into treatment strategies to improve outcomes in these fields. His work has played a role in the approval of myeloma therapies that have significantly advanced the treatment armamentarium, including carfilzomib, pomalidomide, elotuzumab and isatuximab. By working to better understand the biology of these diseases, he hopes to improve treatment options for patients.